Management of non-vital primary molars is challenging due to the natural anatomy of primary teeth, patients' young age, and their behavior toward dental treatment. A simple and effective technique such as Lesion Sterilization and Tissue Repair offers a solution to cases with poor prognosis; however, the medicaments used in this technique have some limitations. This study will evaluate three different medicaments regarding the clinical success, radiographic success, and antibacterial activity.

Start Date01 Aug 2025

Sponsor / Collaborator

Ain Shams University

CTRI/2025/03/083714

/ RecruitingNot ApplicableIIT

Evaluation and Comparison of clinical bracket failure rate of a new orthodontic adhesive modified with silver nanoparticles with conventional orthodontic adhesive : An in vivo study - NIL

Start Date10 Apr 2025

Sponsor / Collaborator-

NCT06899672

/ Not yet recruitingNot ApplicableIIT

Analyzing the Effect of Disinfection Additives on the Linear Dimensional Stability of Dental Alginate Impressions: A Quasi-Experimental Comparative Study

This quasi-experimental comparative study investigates the effects of incorporating various self-disinfecting agents-0.2% Chlorhexidine (CHX), 1% Chitosan solution, 0.2% Silver Nitrate (AgNO3), green-synthesized Silver Nanoparticles (AgNPs), and 15% PVP-Iodine-on the linear dimensional stability of dental alginate impressions. Alginate is widely used in dentistry but is prone to dimensional changes and contamination. This study aims to assess whether integrating these disinfectants can reduce microbial risks without compromising the material's dimensional accuracy, thereby improving infection control and the precision of dental prostheses

Start Date01 Apr 2025

Sponsor / Collaborator

Altamash Institute of Dental Medicine

100 Clinical Results associated with Silver Nitrate

100 Translational Medicine associated with Silver Nitrate

100 Patents (Medical) associated with Silver Nitrate

67,153

Literatures (Medical) associated with Silver Nitrate

01 Dec 2025·Energy and Climate Change

Solar assisted generation of plasmonic silver photocatalyst for wastewater remediation and green hydrogen production

Author: Kumari, Preeti ; Kumar, Aditya

The present study aims to develop sustainable technologies to address the imperative problems of water pollution and energy crisis.This research involves the solar-driven synthesis of a plasmonic silver photocatalyst with properties that aid in environmental and energy applications.The structural, optical, and catalytic properties of the developed photocatalyst are investigated using several anal. techniques, including XRD, XPS, UV-Vis, FESEM, HRTEM, and Raman spectroscopy.The developed photocatalyst is capable of degradation of organic pollutants present in wastewater.The photodegradation capability of photocatalyst is assessed through a comprehensive study of the reaction kinetics involved and the determination of quantum efficiency.Moreover, the photocatalyst also contributes to transition to a green economy via hydrogen production through water splitting.Although the solar-to-hydrogen efficiency of the silver photocatalyst is not appreciable but it paves out way for the development of an efficient photocatalyst by doping or using it as a co-catalyst with semiconductor materials.Thus, the entire study contributes significantly to the development of a clean and sustainable future and takes a step towards the transformation to a renewable energy-based economy.

01 Sep 2025·Talanta

Aptamer cleavage optimization, binding mechanism analysis, and dual-chemiluminescence sensor for microcystin detection

Article

Author: Fan, Zhenlin ; Han, Qinqin ; Song, Yuzhu ; Zhang, Jingping ; Zhang, Jinyang ; Kang, Xuning ; Peng, Zhongmei

This study aimed to develop a high-affinity and highly specific aptamer, microcystins (MCs)-12 using Capture-Systematic Evolution of Ligands by Exponential Enrichment technology based on immobilized libraries. This aptamer simultaneously recognized three conformations of microcystins (MC-LR, MC-RR, and MC-YR). The stem-loop structure of the aptamer sequence MCs-12 was cleaved and optimized by removing the bases step by step. The optimized sequence M-Apt-6, which had an affinity for MCs, was obtained with only 27 bases. In addition, the possible binding sites and mechanisms of M-Apt-6 for MC-LR, MC-RR, and MC-YR were predicted by circular dichroism, molecular docking, and molecular dynamics simulations. A chemiluminescence sensor was developed based on M-Apt-6 to detect MC-LR, MC-RR, and MC-YR in Dianchi Lake water simultaneously. The M-Apt-6 aptamer specifically bound to MCs. The aptamer not bound to MCs was adsorbed on AuNPs to produce a testable chemiluminescent signal in a luminol-AgNO₃ or luminol-H₂O₂ system. The aggregation of AuNPs induced by the MCs/M-Apt-6 complex catalyzed the luminol-AgNO₃ or luminol-H₂O₂ chemiluminescence reactions. The results showed a significant linear relationship between chemiluminescence intensity and MCs concentration. The luminol-AgNO₃ and luminol-H₂O₂ systems showed good linearity for MCs concentration in the range of 0.5-25.0 ng/mL and 0.5-100.0 ng/mL, with the detection limits of 0.22 ng/mL and 0.01 ng/mL, respectively.

01 Aug 2025·Separation and Purification Technology

Construction of novel CoMoO4/AgVO3 heterojunction with abundant oxygen vacancies for efficient photocatalytic hydrogen evolution

Author: Wang, Kai ; Wang, Miao ; Jin, Zhiliang

To address the limitations of CoMoO₄ photocatalysts (e.g., high recombination rate of photogenerated electron-hole pairs and low light energy utilization), a novel CoMoO₄/AgVO₃ photocatalyst enriched with oxygen vacancies (OV) was constructed and the photocatalytic hydrogen production ability under visible light irradiation was investigated.The exptl. results indicate that the hydrogen production efficiency of CoMoO₄/AgVO₃-30 reaches 3049.28μmol g^-1h^-1, which is 5.07 times higher than that of CoMoO₄ and 8.89 times higher than that of AgVO₃.Based on the XPS, UPS and DFT characterization results, it can be inferred that, since the work function of CoMoO₄ compared to is lower than that of AgVO₃, the electrons of CoMoO₄ undergo transfer AgVO₃ when the two are in contact, thus optimizing the energy band structure.In-situ XPS results further reveal that under photoexcitation conditions, the electrons of CoMoO₄ are continuously transferred to AgVO₃, consistent with the S-scheme electron transfer mechanism, which facilitates the spatial separation of photogenerated carriers and holes.Furthermore, the abundant OV in CoMoO₄/AgVO₃ enhances the capture of photogenerated electrons and promotes the hydrogen evolution reaction.S-scheme electron transfer mechanism synergizes with abundant OV to boost photocatalytic hydrogen evolution activity.

News (Medical) associated with Silver Nitrate

16 Apr 2024

·www.prnewswire.com

Journal of the American Chemical Society Differentiates EVŌQ Nano's EVQ-218 Nanoparticle as a New Form of Silver; Holds Promise for Widespread Medical Applications

EVQ-218 is the first stable, nonemissive, pure metal nanoparticle on par with NIST standards for ideal materials. The 'clean and green' EVQ-218 nanosilver is free of toxic ion emissions. SALT LAKE CITY, April 16, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries, today announced that the American Chemical Society journal, ACS Omega, published a peer-reviewed study characterizing and differentiating the company's lead asset, EVQ-218, as a new form of silver nanoparticle (AgNP). EVQ-218 meets the highest standards set by the National Institute of Standards and Technology (NIST) while avoiding the limitations and safety risks of other nanosilvers. Continue Reading Engineered by EVŌQ Nano, EVQ-218 is the first and only stable, non-ionic silver nanoparticle (AgNP) for medical applications. The characterization of EVQ-218 is timely as the rise of antimicrobial resistance (AMR) has caused a surge of research into safer, more effective treatments. Prioritized by the World Health Organization as one of the top 10 global public health threats, AMR threatens the effective prevention and treatment of infections.1 "The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs," said Shaun Rothwell, EVŌQ Nano CEO. While silver's antibacterial qualities have been known for centuries,2,3 it is widely established that the antimicrobial activity is due to ion emission, which poses toxicity risks for biomedical and consumer product applications.4-7 Realizing Silver's Therapeutic Potential Compared to traditional nanosilvers, EVQ-218 is differentiated due to its characterization and behavior as the first stable, nonemissive, pure silver nanoparticle that is on par with NIST standards for ideal materials, making it a superior candidate for biomedical and consumer product use.8 "Not only does EVQ-218 match NIST's standards for particle size and shape, but it possesses an ultrastable shell structure that completely inhibits ion emission — a first for a pure metal nanoparticle," said Bretni Kennon, Ph.D., principal investigator, EVŌQ Nano. Novel Mechanism of Action EVQ-218's antimicrobial efficacy is rooted in its ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This blocks activation of bacterial mutations that contribute to AMR. In contrast, nanosilvers with ions rupture cell walls, triggering activation of AMR pathways. Multi-Patented Laser Nanofabrication Process EVQ-218 is a high-energy produced silver nanoparticle with a method of manufacture that avoids chemical or biological synthesis. Ablation via a multiple, cross-laser system occurs at temperatures and pressures akin to diamond formation. The patented single-step, high-volume laser process generates stable, pure metal nanoparticles directly into pharmaceutical-grade water.8 The sub-10 nm spherical nanoparticles have an ultrastable shell structure that inhibits the hallmark ion emission that occurs in other nanosilver species.8 The resulting particle size and shape characteristics prevent the need for stabilizing chemistries.8 When factoring in shelf life, EVQ-218 maintains uniform stability for years; traditional nanosilvers degrade within weeks.8 These properties make EVQ-218 an attractive clean and green alternative to traditional nanosilvers.8 Advancing Antimicrobial Solutions With EVQ-218 To address the critical issue of healthcare-associated infections (HAIs), primarily caused by indwelling devices like catheters, EVŌQ Nano is collaborating with leading catheter manufacturers. By infusing EVQ-218 throughout the polymer, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.9 EVŌQ Nano has also received two grants from the Cystic Fibrosis Foundation for the development of an inhaled therapeutic to treat pulmonary bacterial infections. The company had its Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in March and, with the agency's feedback, is confidently advancing toward Phase I clinical trials. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates uniform, sub-10 nm nanoparticles with distinct surface chemistry. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Walsh TR, Gales AC, Laxminarayan R, Dodd PC. Antimicrobial resistance: addressing a global threat to humanity. PLoS Med. 2023 Jul 3;20(7):e1004264. doi: 10.1371/journal.pmed.1004264. PMID: 37399216; PMCID: PMC10317217. Alexander JW. History of the medical use of silver. Surg Infect. 2009;10(3):289. Medici S, Peana M, Nurchi VM, Zoroddu MA. Medical uses of silver—history, myths, and scientific evidence. J Med Chem. 2019;62:5923−5943. Stabryla LM, Johnston KA, Millstone JE, Gilbertson LM. Emerging investigator series: it's not all about the ion: support for particle-specific contributions to silver nanoparticle antimicrobial activity Environ Sci Nano. 2018;5:2047−2068. Kedziora A, Speruda M, Krzyzewska E, Rybka J, Bugla-Ploskonska G. Similarities and differences between silver ions and silver in nanoforms as antibacterial agents. Int J Mol Sci. 2018;19:444. Slavin YN, Asnis J, Häfeli UO, Bach H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology. 2017;15:65. Liao C, Li Y, Tjong SC. Bactericidal and cytotoxic properties of silver nanoparticles. Int J Mol Sci. 2019;20:449. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024;9(7):7891-7903. doi: 10.1021/acsomega.3c07745. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. . SOURCE EVOQ Nano

08 Apr 2024

·www.massdevice.com

Orthobond wins FDA de novo approval for antibacterial technology that could have vast device applications

The Monmouth Junction, New Jersey-based device developer says it’s the first time the FDA has granted a de novo request for a non-eluting coating designed to actively kill bacteria that could contaminate the surface of a medical device. Orthobond was founded by Princeton University Chemistry Professor Emeritus Jeffrey Schwartz and the late Dr. Gregory Lutz, who was physiatrist-in-chief emeritus at the Hospital for Special Surgery. Lutz died of cancer on March 5, but knew FDA approval was on the horizon. Orthobond CEO David Nichols called the FDA approval a “testament to Gregory’s legacy” in a statement shared with MassDevice. “We are proud to be able to carry it on into this next chapter.” The first application will be Ostaguard-treated SeaSpine Mariner pedicle screws, according to FDA records. Those could be used in patients early next year, Nichols (a former Zimmer Biomet executive) said in an exclusive interview with MassDevice. Orthobond’s proprietary technology is a quaternary ammonium compound coating that’s highly effective in neutralizing the different bacteria responsible for most device-related infections and can be applied to almost any device, he said. Medical Design & Outsourcing: How Orthobond’s antimicrobial coating prevents contamination of medical devices Unlike antibiotic-eluting devices, Ostaguard doesn’t use antibiotics so there’s no risk of creating drug-resistant superbugs. And while antimicrobial materials like silver, palladium and copper can kill bacteria, those toxic metals aren’t biocompatible with human tissue, Nichols said. “Those have been the barriers for decades,” he said. “[Ostaguard] is a brand new category for the FDA. It doesn’t come off the device — it is considered a device — and it actively kills bacteria.” The FDA gave the new category a generic name of “spinal fusion device with quaternary ammonium compound coating,” defined as “a rigid metallic implant device or system comprised of single or multiple components intended to facilitate fusion in skeletally mature patients. The device includes a quaternary ammonium compound coating that is covalently bonded to the device. Where applied, the coating is intended to reduce microbial contamination on the surface of the device prior to implantation. The device does not contain antimicrobial agents that act within or on the body and this device type does not include combination products.” According to an approval letter shared by Ostaguard, the FDA classified the product as a Class II device and established special controls, which Orthobond declined to divulge. While Orthobond said it found no evidence of local or systemic toxicity in sheep, guinea pig and canine testing, the coating technology has not been evaluated in human clinical trials. Orthobond says the technology’s intellectual property is protected through 2037 through three patent fences covering the covalent surface chemistry, antimicrobial layer and analytical processes, including 27 patents and 12 pending applications. Orthobond intends to seek 510(k) clearances for additional orthopedic spinal implant indications before expanding to other fields such as joint reconstruction, oncology, sports medicine, plastic surgery and cardiovascular. “We’re working on a neuromodulation device, there’s a trauma device we’re working on, and we’re going to work on a cochlear implant,” Nichols said. “If you use a cochlear implant and it gets infected, you pretty much lose your hearing. That’s something that they want to solve.” “We’d like to be as broad as possible,” he continued. “… This should be on all devices that get used. There’s no reason why not. If you’re going to sterile package them, why don’t you put an antibacterial on them?” Beyond medtech, Orthobond leaders believe the technology could also have commercial and industrial applications in areas such as automotive, consumer products and textiles. about how Orthobond’s Ostaguard antibacterial technology works and additional potential applications at our sister site, Medical Design & Outsourcing.

Drug Approval

22 Feb 2024

·www.prnewswire.com

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 Billion Catheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care. More than 1 million HAIs occur annually in the U.S., causing significant morbidity and mortality. The majority of HAIs are associated with indwelling devices, with catheter-associated urinary tract infections (CAUTIs) representing the most common type.1 Rising antimicrobial resistance has compounded this health threat — as up to one-third of CAUTIs in the U.S. are drug resistant,2 with annual treatment cost exceeding $13 billion.3 "For nearly 30 years, companies have tried to create antimicrobial devices, but the performance never proved effective. Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano. "With its proven ability to resist microbial growth and biofilm formation without triggering antimicrobial resistance, this platform has the potential to significantly impact device-related infections — much like the antibiotic revolution transformed infectious disease treatment a century ago." By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.4 Strong Antimicrobial Efficacy In collaboration with the world's leading catheter manufacturers, extensive lab testing on catheters, luers, and fittings manufactured with EVŌQ Nano's EVQ-218 nanoparticle infused throughout the polymer, demonstrated: Strong antibacterial, antifungal, and antibiofilm efficacy Staphylococcus aureus: 7-8 log reduction Pseudomonas aeruginosa: 6-7.5 log reduction Candida albicans: 5-6.5 log reduction Broad-spectrum activity against 64 bacterial strains tested No degradation of antimicrobial activity; sustained presence for the life of the product Novel Mechanism of Action Existing antimicrobial solutions for medical devices have fallen short. Coatings slough off, degrade over time, and can only be applied to limited materials. While silver is a proven and powerful antimicrobial, current antibacterial catheters externally coated with silver lose efficacy once inserted due to natural sloughing of the material coupled with the short life of silver ions. This combination hinders the antimicrobial activity of current products. EVQ-218 is the first and only non-ionic silver nanoparticle. Extensive studies characterize EVQ-218 as a new form of silver nanoparticle (AgNP), manufactured with EVŌQ Nano's multi-patented nanofabrication process that requires only laser energy, ultrapure water, and pure silver metal.5 Unlike standard silver nanoparticles, EVQ-218 has true "bare" silver surface chemistry, with greater group stability that mitigates the need for added stabilizers.5 The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs. EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This avoids activation of bacterial mutations that contribute to antimicrobial resistance. In contrast, nanoparticles with silver ions rupture cell walls, triggering activation of resistance pathways. By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates nanoparticles that are uniformly sized, surfactant-free, with consistent spherical morphology, and no ion emissions under standard and stressed conditions. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Health Care-Associated Infections. Patient Safety Network. Published September 7, 2019. Accessed November 21, 2023. Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. Res Rep Urol. 2022; Apr 4;14:109-133. doi: 10.2147/RRU.S273663. PMID: 35402319; PMCID: PMC8992741 Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. Content last reviewed November 2017. Accessed January 19, 2024. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024. doi: 10.1021/acsomega.3c07745 Niedermeyer W, inventor; ATTOSTAT Inc., assignee. Method and apparatus for production of uniformly sized nanoparticles. US patent 9,849,512. November 9, 2017. Dimpka CO, Calder A, Gajjar P, Merugu S, Huang W, Britt DW, McLean JE, Johnson WP, Anderson AJ. Interaction of silver nanoparticles with an environmentally beneficial bacterium, Pseudomonas chlororaphis. J. Haz. Mat. 2011; 188:428-435. doi: 10.1016/j.jhazmat.2011.01.118 SOURCE EVŌQ Nano

100 Deals associated with Silver Nitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01730	-	D08AL01	DB11080

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Warts	Australia	Sutherland Medical Pty Limited	26 Jul 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05130814 (RISE_UP, CTgov)	Not Applicable	Pressure Ulcer	48	bandage+zinc+hyaluronic acid sodium salt+hyaluronic acid+metallic silver (Control Group)	smrlxoeqdt(ynmcsxzhqk) = higmzvqlwm nlknpscneh (xuelxkasgt, hetnwhvine - bbgjckoebu) View more	-	28 Jan 2025
				bandage+zinc+hyaluronic acid sodium salt+hyaluronic acid+metallic silver (EmoLED Group)	smrlxoeqdt(ynmcsxzhqk) = ieyofwsiko nlknpscneh (xuelxkasgt, hbpypzgmxp - ikhzofnhmw) View more
NCT02519738 (CTgov)	Phase 3	-	52	Silver Nitrate (Silver Nitrate)	xcwirhuqoz(igurohshgl) = xwzudexlku qlmadciesk (mkxdhlobut, rothjovafe - ysyqlqjmld) View more	-	25 Jan 2022
				Triamcinolone+Kenalog (Kenalog (Triamcinolone))	xcwirhuqoz(igurohshgl) = xmevsdgqjt qlmadciesk (mkxdhlobut, wclemlvaan - sknzyykiqc) View more
AACR2020	Not Applicable	Glioblastoma Multiforme	-	Silver nanoparticles	jhbsbdwicu(lgbliliopw) = xtvtqhphmr cwbyihnrzu (jwzjkmdmjy )	Positive	15 Aug 2020
				Silver nanoparticles + low-level He-Ne laser	jhbsbdwicu(lgbliliopw) = kndbxfgbmo cwbyihnrzu (jwzjkmdmjy )
ERS2016	Not Applicable	Emphysema	12	Silver Nitrate solution 0.5%	(dcqjuxzkbs) = qforjehurt fmotikujwp (agkfrbkqkq ) View more	Positive	01 Sep 2016
ACTRN12609000451202 (Pubmed \| J Burn Care Res)	Phase 3	Burns	89	Silver-Based Burns Dressing	tfdsrgcayf(aurugejibd) = obipqodfew gxrmszipmj (qqkxnoaslo )	-	01 Jan 2016
				Silver-Based Burns Dressing	tfdsrgcayf(aurugejibd) = bocjttfcdf gxrmszipmj (qqkxnoaslo )
NCT00675922 (Soaks, CTgov)	Phase 2/3	Burns	98	Sulfamylon (Percent Infections:Sulfamylon Site)	ensokewhjf(mucbbgwqkg) = tsenlrydyc cnfcsoxudr (wdiqnyxjeh, ypyjopodvl - rbuvstngug)	-	18 Jan 2013
				Silver Nitrate (Percent Infections: Silver Nitrate Site)	ensokewhjf(mucbbgwqkg) = hjcocdwefi cnfcsoxudr (wdiqnyxjeh, dkzsokvogu - jhbyjakaja)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Silver Nitrate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation